このエントリーをはてなブックマークに追加
ID 48853
フルテキストURL
著者
Kojima, Toru Division of Surgical Oncology, Department of Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Hashimoto, Yuuri Division of Surgical Oncology, Department of Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Watanabe, Yuichi Division of Surgical Oncology, Department of Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kagawa, Shunsuke Division of Surgical Oncology, Department of Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Uno, Futoshi Division of Surgical Oncology, Department of Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kuroda, Shinji Division of Surgical Oncology, Department of Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Tazawa, Hiroshi Center for Gene and Cell Therapy, Okayama University Hospital
Kyo, Satoru Department of Obstetrics and Gynecology, Kanazawa University School of Medicine
Mizuguchi, Hiroyuki Department of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University
Urata, Yasuo Oncolys BioPharma Inc.
Tanaka, Noriaki Division of Surgical Oncology, Department of Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Fujiwara, Toshiyoshi Division of Surgical Oncology, Department of Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
抄録
The presence of circulating tumor cells (CTCs) in the peripheral blood is associated with short survival, making the detection of CTCs clinically useful as a prognostic factor of disease outcome and/or a surrogate marker of treatment response. Recent technical advances in immunocytometric analysis and quantitative real-time PCR have made it possible to detect a few CTCs in the blood; however, there is no sensitive assay to specifically detect viable CTCs. Here, we report what we believe to be a new approach to visually detect live human CTCs among millions of peripheral blood leukocytes, using a telomerase-specific replication-selective adenovirus expressing GFP. First, we constructed a GFP-expressing attenuated adenovirus, in which the telomerase promoter regulates viral replication (OBP-401; TelomeScan). We then used OBP-401 to establish a simple ex vivo method that was able to detect viable human CTCs in the peripheral blood. The detection method involved a 3-step procedure, including the lysis of rbc, the subsequent addition of OBP-401 to the cell pellets, and an automated scan using fluorescence microscopy. OBP-401 infection increased the signal-to-background ratio as a tumor-specific probe, because the fluorescent signal was amplified only in viable, infected human tumor cells, by viral replication. This GFP-expressing virus-based method is remarkably simple and allows precise enumeration of CTCs.
発行日
2009-10-01
出版物タイトル
The Journal of Clinical Investigation
119巻
10号
出版者
American Society for Clinical Investigation
開始ページ
3172
終了ページ
3181
ISSN
0021-9738
NCID
AA00695520
資料タイプ
学術雑誌論文
プロジェクト
ナノバイオ標的医療の融合的創出拠点
オフィシャル URL
http://www.jci.org/articles/view/38609
言語
English
OAI-PMH Set
岡山大学
著作権者
© 2009, American Society for Clinical Investigation
論文のバージョン
publisher
査読
有り
DOI
PubMed ID
Web of Sience KeyUT